Bibliography
- Smith BH, McNaughton FL. Mysoline, a new anticonvulsant drug – its value in refractory cases of epilepsy. Can Med Assoc J 1953;68:464-7
- Garcia P. Seizure remission in adults with intractable epilepsy: not just a pipe dream. Epilepsy Curr 2008;8:95-6
- Pollard JR, French J. Antiepileptic drugs in development. Lancet Neurol 2006;5:1064-7
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:315-9
- Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006;129:617-24
- Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the ILAE and the IBE. Epilepsia 2005;46:470-2
- Gross RA. A brief history of epilepsy and its therapy in the western hemisphere. Epilepsy Res 1992;12:65-74
- Löscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res 1994;17:95-134
- Klitgaard H. Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol Scand 2005;112(Suppl 181):68-72
- Brodie MJ, Shorvon SD, Canger R, et al. Commission on European affairs: appropriate standards of epilepsy care across Europe. Epilepsia 1997;38:1245-50
- Peterman MG. Therapy of epilepsy in children. Am J Psychiat 1936;92:1433-8
- Laroche SM, Helmers SL. The new antiepileptic drugs – scientific review. J Am Med Assoc 2004;291:605-14
- Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005;46:858-77
- French JA. Refractory epilepsy: clinical overview. Epilepsia 2007;48(Suppl 1):3-7
- Elger CE. Pharmacoresistance: modern concept and basic data derived from human brain tissue. Epilepsia 2003;44(Suppl 5):9-15
- Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006;129:18-35
- Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999;34:109-22
- French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Neurology 2004;62:1261-73
- Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602
- Löscher W. Drug transporters in the epileptic brain. Epilepsia 2007;48(Suppl 1): 8-13
- Beck H. Plasticity of antiepileptic drug targets. Epilepsia 2007;48(Suppl 1):14-18
- Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6:397-406
- Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007;48:43-58
- Téllez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, Wiebe S. Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain 2007;130:334-45
- Amar AP. Vagus nerve stimulation for the treatment of intractable epilepsy. Expert Rev Neurother 2007;7:1763-73
- Theodore WH, Fisher RS. Brain stimulation for epilepsy. Lancet Neurol 2004;3:111-8
- Cohen-Gadol AA, Britton JW, Wetjen NM, et al. Neurostimulation therapy for epilepsy: current modalities and future directions. Mayo Clin Proc 2003;78:238-48
- Boison D. Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 2007;5:115-25
- Löscher W, Gernert M, Heinemann U. Cell and gene therapies in epilepsy – promising avenues or blind alleys? Trends Neurosci 2008;31:62-73
- Avoli M, Louvel J, Pumain R, Köhling R. Cellular and molecular mechanisms of epilepsy in the human brain. Prog Neurobiol 2005;77:166-200
- Ribak CE, Dashtipour K. Neuroplasticity in the damaged dentate gyrus of the epileptic brain. Prog Brain Res 2002;136:319-28
- Oby E, Janigro D. The blood–brain barrier and epilepsy. Epilepsia 2006;47:1761-74
- De Lanerolle NC, Lee TS. New facets of the neuropathology and molecular profile of human temporal lobe epilepsy. Epilepsy Behav 2005;7:190-203
- Pitkänen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002;1:173-81
- Nearing K, Madhavan D, Devinsky O. Temporal lobe epilepsy: a progressive disorder? Rev Neurol Dis 2007;4:122-7
- Scharfman HE. The neurobiology of epilepsy. Curr Neurol Neurosci Rep 2007;7:348-54
- Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-64
- Mizielinska SM. Ion channels in epilepsy. Biochem Soc Trans 2007;35:1077-9
- Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia 1989;42(Suppl 3):8-12
- Laroche SM, Helmers SL. The new antiepileptic drugs – clinical applications. J Am Med Assoc 2004;291:615-20
- Engel J Jr. Excitation and inhibition in epilepsy. Can J Neurol Sci 1996;23:167-74
- Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 2002;23:113-8
- Faingold CL. Emergent properties of neuronal networks as targets for pharmacology: application to anticonvulsant drug action. Prog Neurobiol 2004;72:55-85
- Margineanu DG, Klitgaard H. Can gap-junction blockade preferentially inhibit neuronal hypersynchrony vs. excitability? Neuropharmacol 2001;41:377-83
- Mann EO, Mody I. The multifaceted role of inhibition in epilepsy: seizure-genesis through excessive GABAergic inhibition in autosomal dominant nocturnal frontal lobe epilepsy. Curr Opin Neurol 2008;21:155-60
- Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16:197-201
- Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31
- Volk HA, Löscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005;128:1358-68
- Luurtsema G, Molthoff CF, Schuit RC, et al. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol 2005;32:87-93
- Bankstahl JP, Kuntner C, Abrahim A, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med 2008;49:1328-35
- Rambeck B, Jürgens UH, May TW, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006;47:681-94
- Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New Engl J Med 2003;348:1442-8
- Baltes S, Fedrowitz M, Luna Tortos C, et al. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007;320:331-43
- Baltes S, Gastens AM, Fedrowitz M, et al. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacol 2007;52:333-46
- Crowe A, Teoh YK. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J Drug Target 2006;14:291-300
- Tan NCK, Heron SE, Scheffer IE, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004;63:1090-2
- Ellerkmann RK, Remy S, Chen J, et al. Molecular and functional changes in voltage-dependent Na+ channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neurosci 2003;119:323-33
- Su H, Sochivko D, Becker A, et al. Upregulation of a T-type Ca2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus. J Neurosci 2002;22:3645-55
- Brooks-Kayal AR, Shumate MD, Jin H, et al. Selective changes in single cell GABAA receptor subunit expression and function in temporal lobe epilepsy. Nat Med 1998;4:1166-72
- Shah MM, Anderson AE, Leung V, et al. Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons. Neuron 2004;44:495-508
- Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002;5:767-74
- Surges R, Freiman TM, Feuerstein TJ. Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. Epilepsia 2003;44:150-6
- Remy S, Gabriel S, Urban BW, et al. A novel mechanism underlying drug-resistance in chronic epilepsy. Ann Neurol 2003;53:469-79
- Rhodes TH, Vanoye CG, Ohmori I, et al. Sodium channel dysfunction in intractable childhood epilepsy with generalized tonic-clonic seizures. J Physiol 2005;569.2:433-45
- Aronica E, Boer K, Redeker S, et al. Differential expression patterns of chloride transporters, Na+-K+-2Cl– cotransporter and K+-2Cl–cotransporter, in epilepsy-associated malformations of cortical development. Neuroscience 2007;145:185-96
- Munakata M, Watanabe M, Otsuki T, et al. Altered distribution of KCC2 in cortical dysplasia in patients with intractable epilepsy. Epilepsia 2007;48:837-44
- Avoli M, Louvel J, Pumain R, Köhling R. Cellular and molecular mechanisms of epilepsy in the human brain. Prog Neurobiol 2005;77:166-200
- Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005;46:1724-43
- Gorter JA, van Vliet EA, Aronica E, et al. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci 2006;26:11083-110
- Oprica M, Eriksson C, Schultzberg M. Inflammatory mechanisms associated with brain damage induced by kainic acid, with special reference to the interleukin-1 system. J Cell Mol Med 2003;7:127-40
- Eid T, Williamson A, Lee TS, et al. Glutamate and astrocytes – key players in human mesial temporal lobe epilepsy? Epilepsia 2008;49(Suppl. 2):42-52
- Spencer SS, Kim J, De Lanerolle N, Spencer DD. Differential neuronal and glial relations with parameters of ictal discharge in mesial temporal lobe epilepsy. Epilepsia 1999;40:708-12
- Jabs R, Seifert G, Steinhäuser C. Astrocytic function and its alteration in the epileptic brain. Epilepsia 2008;49(Suppl 2):3-12
- Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 2005;6:626-40
- Nemani VM, Binder DK. Emerging role of gap junctions in epilepsy. Histol Histopathol 2005;20:253-9
- Söhl G, Maxeiner S, Willecke K. Expression and functions of neuronal gap junctions. Nat Rev Neurosci 2005;6:191-200
- Laird DW. Life cycle of connexins in health and disease. Biochem J 2006;394:527-43
- Rouach N, Avignone E, Même W, et al. Gap junctions and connexin expression in the normal and pathological central nervous system. Biol Cell 2002;94:457-75
- Naus CC, Bechberger JF, Paul DL. Gap junction gene expression in human seizure disorder. Exp Neurol 1991;111:198-203
- Fonseca CG, Green CR, Nicholson LF. Upregulation in astrocytic connexin 43 gap junction levels may exacerbate generalized seizures in mesial temporal lobe epilepsy. Brain Res 2002;929:105-16
- Nilsen KE, Kelso ARC, Cock HR. Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy. Epilepsia 2006;47:1169-75
- Pauwels EKJ, Erba P, Mariani G, Gomes CMF. Multidrug resistance in cancer: its mechanism and its modulation. Drug News Perspect 2007;20:371-7
- Stacey WC, Litt B. Technology insight: neuroengineering and epilepsy – designing devices for seizure control. Nat Clin Pract Neurol 2008;4:190-201
- Nilsen KE, Cock HR. Focal treatment for refractory epilepsy: hope for the future? Brain Res Rev 2004;44:141-53
- Hartman AL, Vining EP. Clinical aspects of the ketogenic diet. Epilepsia 2007;48:31-42
- Dragunow M. The adult human brain in preclinical drug development. Nat Rev Drug Disc 2008;7:659-66